Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations

Executive Summary

Sarepta committed up to $562m for European and other rights to Summit’s lead DMD drug candidate ezutromid plus additional fees for other utrophin modulators in a deal announced on Oct. 4 that could enable combination therapy regimens.


Related Content

In DMD, Summit Falls Well Short Of Peak It Hoped For
Summit DMD Data Intrigue But Longer-Term Results Awaited
Biopharma Quarterly Dealmaking Statistics, Q4 2016
Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates
Sarepta Snaps Up Gene Therapy Approaches to DMD
Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts